Background: Bladder cancer preservation treatment achieved 5/10-year overall survival rates comparable to those of radical cystectomy. Bladder-preserving trials have recommended coverage of pelvic lymph nodes (LN) in radiation portals (micrometastases in pelvic LN 25 to 44%). Gemcitabine-based radiotherapy did not include the pelvic LN in the radiation portals to minimize bowel toxicity. However, the pelvic LN irradiation debate has been highlighted. The present study aimed to evaluate the role of pelvic LN irradiation in negative node, bladder cancer.
Method: A prospective study was conducted from October 2017 to February 2020 at the South Egypt Cancer Institute. Bladder cancer Patients with cT1-3, N0, and M0 underwent maximum TURBT and were then randomized into two arms: Group A: Bladder-only irradiation (52.5 GY/20 frs); Group B: Pelvic nodal irradiation with weekly gemcitabine 100mg/m2
Statistical analysis: SPSS Statistics (version 26.0, IBM), descriptive (means and SD), chi-square test for qualitative variables, independent student t-test, and survival analysis (Kaplan-Meier).
Results: Patients aged 37 to 76 years old and 32 to 82 years old in groups A and B, respectively. Cases were Stage III in groups A, II, and III in B. Both groups showed similar local control rates (90% and 92%, respectively). Favorable toxicity profile group A schedule emphasizes high local control with low-grade intestinal toxicity (no G3 enteritis). Unexpectedly, Group A showed significantly higher progression free survival (PFS over Group B (P < 0.034).
Conclusion: Bladder-only chemoradiation has non-inferior local control of node-negative bladder cancer with significantly higher PFS. The pelvic nodal radiation field has an unfavorable toxicity profile (higher G2 enteritis). |
- Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y, et al. Electronic address: clinicalguidelines@esmo.org. Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(3):244-58. doi: 10.1016/j.annonc.2021.11.012. PMID: 34861372.
- Cancer Stat Facts: Bladder Cancer. NIH NCI: Surveillance, Epidemiology, and End Results Program; 2023. Available from: https://seer.cancer.gov/ /html/urinb.html
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. doi: 10.3322/caac.21492. Erratum in: CA Cancer J Clin. 2020;70(4):313. doi: 10.3322/caac.21609. PMID: 30207593.
- Patel SA, Liu Y, Solanki AA, Baumann BC, Efstathiou JA, Jani AB, et al. Bladder only versus bladder plus pelvic lymph node chemoradiation for muscle-invasive bladder cancer. Urol Oncol. 2023;41(7):325.e15-325.e23. doi: 10.1016/j.urolonc.2022.12.011. PMID: 36725382.
- Lewis S, Murthy V, Mahantshetty U, Shrivastava SK. Incidental dose to pelvic nodes in bladder-only radiotherapy: Is it clinically relevant? Technol Cancer Res Treat. 2017;16(3):382-7. doi: 10.1177/1533034617691409. PMID: 28168933; PMCID: PMC5616055.
- Mitin T, Hunt D, Shipley WU, Kaufman DS, Uzzo R, Wu CL, et al. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial. Lancet Oncol. 2013;14(9):863-72. doi: 10.1016/S1470-2045(13)70255-9. PMID: 23823157; PMCID: PMC3955198.
- Baumann BC, Guzzo TJ, He J, Vaughn DJ, Keefe SM, Vapiwala N, et al. Bladder cancer patterns of pelvic failure: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys. 2013;85(2):363-9. doi: 10.1016/j.ijrobp.2012.03.061. PMID: 22658217.
- Patel SA, Liu Y, Solanki AA, Baumann BC, Efstathiou JA, Jani AB, et al. Bladder only versus bladder plus pelvic lymph node chemoradiation for muscle-invasive bladder cancer. Urol Oncol. 2023;41(7):325.e15-325.e23. doi: 10.1016/j.urolonc.2022.12.011. PMID: 36725382.
- Hall E, Hussain SA, Porta N, Lewis R, Crundwell M, Jenkins P, et al. Chemoradiotherapy in muscle-invasive bladder cancer: 10-yr follow-up of the phase 3 randomised controlled BC2001 trial. Eur Urol. 2022;82(3):273-9. doi: 10.1016/j.eururo.2022.04.017. PMID: 35577644.
- Mertens LS, Meijer RP, Meinhardt W, van der Poel HG, Bex A, Kerst JM, et al. Occult lymph node metastases in patients with carcinoma invading bladder muscle: incidence after neoadjuvant chemotherapy and cystectomy vs after cystectomy alone. BJU Int. 2014;114(1):67-74. doi: 10.1111/bju.12447. PMID: 24053889.
- Lewis S, Murthy V, Mahantshetty U, Shrivastava SK. Incidental dose to pelvic nodes in bladder-only radiotherapy: Is it clinically relevant? Technol Cancer Res Treat. 2017;16(3):382-7. doi: 10.1177/1533034617691409. PMID: 28168933; PMCID: PMC5616055.
- Marciscano AE, Ghasemzadeh A, Nirschl TR, Theodros D, Kochel CM, Francica BJ, et al. Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapy. Clin Cancer Res. 2018;24(20):5058-71. doi: 10.1158/1078-0432.CCR-17-3427. PMID: 29898992; PMCID: PMC6532976.
- Tunio MA, Hashmi A, Qayyum A, Mohsin R, Zaeem A. Whole-pelvis or bladder-only chemoradiation for lymph node-negative invasive bladder cancer: single-institution experience. Int J Radiat Oncol Biol Phys. 2012;82(3):e457-62. doi: 10.1016/j.ijrobp.2011.05.051. PMID: 21945107.
- Coen JJ, Zhang P, Saylor PJ, Lee CT, Wu CL, Parker W, et al. Bladder preservation with twice-a-day radiation plus fluorouracil/cisplatin or once daily radiation plus gemcitabine for muscle-invasive bladder cancer: NRG/RTOG 0712-a randomized phase II trial. J Clin Oncol. 2019;37(1):44-51. doi: 10.1200/JCO.18.00537. Erratum in: J Clin Oncol. 2021;39(11):1309. doi: 10.1200/JCO.21.00602. PMID: 30433852; PMCID: PMC6354769.
|
